Form 4: Iovance Biotherapeutics Executive Frederick G. Vogt Reports Stock Transactions

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting and tax withholding of restricted stock units.

Summary

• On March 3, 2025, Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reported transactions involving the company's common stock and restricted stock units (RSUs).
• 223,943 shares underlying RSUs vested, and 95,413 shares were withheld by the issuer to satisfy tax obligations at a price of $4.04 per share.
• Following these transactions, Vogt directly owns 349,646 shares of common stock.
• Vogt also holds 41,669 RSUs granted on March 2, 2023, and 333,350 RSUs granted on March 1, 2024, which will vest in equal quarterly installments.

Sentiment

Score: 5

Explanation: This Form 4 filing is a neutral event, simply reporting required insider transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
• The vesting schedule and tax withholding practices are typical for RSU grants in the biotechnology industry.
• Similar filings can be observed for executives at comparable companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead).

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they involve the vesting of previously granted equity compensation.
• Employees holding RSUs may be affected by similar vesting and tax withholding events.

Key Dates